Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Overview
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AsclepiX Therapeutics Inc
Bayer AG
Deciphera Pharmaceuticals Inc
Eddingpharm Inc
Eli Lilly and Co
Exelixis Inc
Pfizer Inc
PharmAbcine Inc
Q BioMed Inc
Samjin Pharm Co Ltd
Teva Pharmaceutical Industries Ltd
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexmetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebastinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TIE2 for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDAU-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kise or Tunica Inter Endothelial Cell Kise or Tyrosine Kise With Ig And EGF Homology Domains 2 or Tyrosine Protein Kise Receptor TEK or Tyrosine Protein Kise Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AsclepiX Therapeutics Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Pipeline by Eddingpharm Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Q BioMed Inc, H2 2019
Pipeline by Samjin Pharm Co Ltd, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019